The Budd-Chiari syndrome
##plugins.themes.academic_pro.article.main##
Abstract
Background: The Budd-Chiari syndrome is a rare disease, often fatal if not treated optimally. It is characterized by a blocked hepatic venous outflow tract.
aim: This review attempted to present pathophysiology, aetiologies,diagnosis and therapeutic modalities of the Budd-Chiari syndrome.
methods: Review of literature.
results: Budd-Chiari syndrome is a complex disease with a wide spectrum of aetiologies and presentations. Hematologic abnormalities, particularly myeloproliferative disorders, are the most common causes of the Budd-Chiari syndrome. The clinical presentation is governed by the extent and rapidity of the hepatic vein occlusion. Doppler-ultrasound, computed tomography or magnetic resonance imaging of hepatic veins and inferior vena cava are usually successful in demonstrating non-invasively the obstacle or its consequences. A therapeutic strategy has been proposed where anticoagulation, correction of risk factors, diuretics and prophylaxis for portal hypertension are used first; then angioplasty for shortlength venous stenosis; then Transjugular Intrahepatic Portosystemic Shunt (TIPS); and ultimately liver transplantation. Treatment progression is dictated by the response to previous therapy. This strategy has achieved 5-year survival rates approaching 70%.Medium-term prognosis depends on the severity of liver disease.
Conclusion: The diagnosis of the Budd-Chiari syndrome must be considered in any patients with acute or chronic liver disease. Management of this syndrome should follow a step by step strategy.
aim: This review attempted to present pathophysiology, aetiologies,diagnosis and therapeutic modalities of the Budd-Chiari syndrome.
methods: Review of literature.
results: Budd-Chiari syndrome is a complex disease with a wide spectrum of aetiologies and presentations. Hematologic abnormalities, particularly myeloproliferative disorders, are the most common causes of the Budd-Chiari syndrome. The clinical presentation is governed by the extent and rapidity of the hepatic vein occlusion. Doppler-ultrasound, computed tomography or magnetic resonance imaging of hepatic veins and inferior vena cava are usually successful in demonstrating non-invasively the obstacle or its consequences. A therapeutic strategy has been proposed where anticoagulation, correction of risk factors, diuretics and prophylaxis for portal hypertension are used first; then angioplasty for shortlength venous stenosis; then Transjugular Intrahepatic Portosystemic Shunt (TIPS); and ultimately liver transplantation. Treatment progression is dictated by the response to previous therapy. This strategy has achieved 5-year survival rates approaching 70%.Medium-term prognosis depends on the severity of liver disease.
Conclusion: The diagnosis of the Budd-Chiari syndrome must be considered in any patients with acute or chronic liver disease. Management of this syndrome should follow a step by step strategy.
Keywords:
Budd-Chiari syndrome, Ascites, Thrombosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS)##plugins.themes.academic_pro.article.details##
References
- Chung RT, Iafrate AJ, Amrein PC, et al. Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. N Engl J Med 2006; 354: 2166-75.
- Wang ZG, Zhang FJ, Yi MQ, Qiang LX. Evolution of management for Budd-Chiari syndrome: a team's view from 2564 patients. ANZ J Surg 2005; 75: 55-63.
- Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364- 71.
- Langlet P, Valla D. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome? Acta Gastroenterol Belg 2002; 65: 155-60.
- Navarro F, Le Moine MC, Fabre JM, et al. Specific vascular complications of orthotopic liver transplantation with preservation of the retrohepatic vena cava: review of 1361 cases. Transplantation 1999; 68: 646-50.
- Wang SL, Sze DY, Busque S, et al. Treatment of hepatic venous outflow obstruction after piggyback liver transplantation. Radiology 2005; 236: 352-9.
- Menon KV, ShahV, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350: 578-85.
- Morrin MM, Pedrosa I, Rofsky NM. Magnetic resonance imaging for disorders of liver vasculature. Top Magn Reson Imaging 2002; 13: 177-90.
- Terasaki M, Kitai T, Morimoto T, et al. Hemodynamics and hepatic energy metabolism in canine model of acute hepatic venous occlusion with mesocaval shunt. Eur Surg Res 1994; 26: 19-27.
- Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-91.
- Valla DC. Primary Budd-Chiari syndrome. J Hepatol 2009; 50: 195-203.
- Hussein K, Bock O, Kreipe H. Histological and molecular classification of chronic myeloproliferative disorders in the Age of JAK2: persistence of old questions despite new answers. Pathobiology 2007; 74: 72-80.
- DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular Disorders of the Liver. Hepatology 2009; 49: 1729-64.
- Mohanty D, Shetty S, Ghosh K, et al. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001; 34: 666-70.
- Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350: 578-85.
- Wolf M, Boyer-Neumann C, Leroy-Matheron C, et al. Functional assay of protein S in 70 patients with congenital and acquired disorders. Blood Coagul Fibrinolysis 1991; 2: 705-12.
- Kyriakidis AV, Vezyrgiannis I, Pyrgioti M. Budd-Chiari syndrome. Ann Gastroenterol 2008; 21: 223-28.
- Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986; 90: 807-11.
- Bismuth E, Hadengue A, Hammel P, Benhamou JP. Hepatic vein thrombosis in Behcet's disease. Hepatology 1990; 11: 969-74.
- Robotti GC, Meister F, Schroeder R. Budd-Chiari syndrome bei Leberechinockokkose. R ofo Fortschr Geb R ontgenstr- Nuklearmed 1985; 142: 511-3.
- Schraut WH, Chilcote RR. Metastatic Wilms' tumor causing acute hepatic-vein occlusion (Budd-Chiari syndrome). Gastroenterology 1985; 88: 576-9.
- Bayraktar Y, Egesel T, Saģlam F, et al. Does hepatic vein outflow obstruction contribute to the pathogenesis of hepatocellular carcinoma? J Clinical Gastroenterology 1998; 27: 67-71.
- Mitchell MC, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 1982; 61: 199-218.
- Hemming AW, Langer B, Greig P, et al. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996; 171: 176-80.
- Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994; 106: 1042-7.
- Bolondi L, Gaiani S, Li Bassi S, et al. Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound. Gastroenterology 1991; 100: 1324-31.
- Kane R, Eustace S. Diagnosis of Budd-Chiari syndrome: comparison between sonography and MR angiography. Radiology 1995; 195:117-121.
- Millener P, Grant EG, Rose S, et al. Color Doppler imaging findings in patients with Budd-Chiari syndrome: correlation with venographic findings. AJR Am J Roentgenol 1993; 161: 307-12.
- Gupta S, Barter S, Phillips GW, et al. Comparison of ultrasonography, computed tomography and 99mTc liver scan in diagnosis of Budd-Chiari syndrome. Gut 1987; 28: 242-7.
- Noone TC, Semelka RC, Siegelman ES, et al. Budd-Chiari syndrome: spectrum of appearances of acute, sub acute, and chronic disease with magnetic resonance imaging. J Magn Reson Imaging 2000; 11: 44-50.
- Kreel L, Freston J, Clain D. Vascular radiology in the Budd- Chiari syndrome. Br J Radiol 1967; 40: 755-9.
- Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73: 21-36.
- Mancuso A. Budd-Chiari syndrome management: Lights and shadows. World J Hepatol 2011; 3: 262-4.
- Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006; 44: 1308-16.
- Rautou PE, Douarin L, Denninger MH, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol 2011; 54: 56-63.
- Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006; 55: 878-84.
- Plessier A. [Budd Chiari syndrome]. Gastroenterol Clin Biol 2006; 30: 1162-9.
- Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol 2012 ; 56: S25-S38.
- Darwish Murad D, Valla DC, de Groen PC, et al. Determinants of survival and the effect of porto systemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-8.
- Fisher NC, McCafferty I, Dolapci M, et al. Managing Budd- Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut 1999; 44: 568-74.
- Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centers. J Hepatol 2006; 44: 520-8.
- Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl 2007; 13: 1285-94.
- Kugelmas M. Budd-Chiari syndrome. Treatment options and the value of liver transplantation. Hepatogastroenterology 1998; 45: 1381-6.
- Garcia-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd- Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808-15.